13.85
-0.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Organon &
From its filings with the US Securities and Exchange Commission
Organon & is based in Jersey City, New Jersey. Its shares trade on NYSE under the ticker OGN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $6.22bn and net income of $187.0m. At that date it held total assets of $12.87bn and shareholders' equity of $752.0m. By region, Int’l accounted for 74.2%, followed by U.S. at 25.8%.
Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers and other institutions. We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom (“UK”). Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.
Our portfolio of products generates sufficient cash flows to support the Company’s strategic initiatives and future growth opportunities. In addition, we are pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging our scale and presence.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 May 2021
- Employees
- 10,000
- Website
- organon.com ↗
- Head office
- 30 HUDSON STREET, JERSEY CITY, NJ, 07302
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Carrie CoxIndependent Chairman of the Board$450,000
- Mr. Kevin AliChief Executive Officer, Director, since 2021$17.1m
- Mr. Matthew WalshChief Financial Officer, Executive Vice President$5.7m
- Mr. Aaron FalcioneChief Human Resources Officer, Executive Vice President
- Mr. Kirke WeaverExecutive Vice President, General Counsel, Corporate Secretary$3.2m
- Dr. Juan FerreiraExecutive Vice President, Head of Research and Development and Chief Medical Officer$3.6m
- Mr. Joseph MorrisseyExecutive Vice President, Head of Manufacturing and Supply$4.1m
- Mr. Vittorio NisitaExecutive Vice President, Head of Enterprise Services & Solutions
- Ms. Rachel StahlerExecutive Vice President, Chief Digital and Growth Officer
- Mr. Robert EssnerIndependent Director$335,000
- Dr. Alan EzekowitzIndependent Director$330,000
- Dr. Helene GayleIndependent Director$320,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 76
- Social
- 73
- Governance
- 30
- Direct emissions (scope 1)
- 30,360 t
- Energy emissions (scope 2)
- 24,479 t
- Value chain emissions (scope 3)
- 1,029,000 t
- Women in the workforce
- 53%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Organon's women's health portfolio includes Nexplanon and NuvaRing for contraception.
- Biosimilars in immunology and oncology treatments expand Organon's market reach.
- Established brands in cardiovascular and respiratory therapies support steady revenue streams.
Weaknesses
- Limited presence in non-opioid pain management compared to competitors.
- Dependence on prescription therapies may limit growth in over-the-counter markets.
- Reliance on drug wholesalers and retailers for product distribution channels.
Opportunities
- Expanding biosimilars portfolio into new therapeutic areas like neurology.
- Growing demand for women's health solutions in emerging markets globally.
- Increasing adoption of digital health platforms for prescription management.
Threats
- Regulatory changes affecting biosimilars approval processes in key markets.
- Intensifying competition in women's health product segments.
- Economic downturns impacting healthcare spending by government agencies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.